Sign in or create an account to add this stock to your watchlist.
About Aptose Biosciences (NASDAQ:APTO)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828
Debt
Debt-to-Equity RatioN/A
Current Ratio7.51
Quick Ratio7.51
Price-To-Earnings
Trailing P/E Ratio-6.92
Forward P/E Ratio-5.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book8.18
Profitability
EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-136.61%
Return on Assets-119.69%
Miscellaneous
Employees23
Outstanding Shares32,900,000
Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How were Aptose Biosciences' earnings last quarter?
Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Tuesday, March, 27th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.01. View Aptose Biosciences' Earnings History.
What price target have analysts set for APTO?
4 brokers have issued 12 month target prices for Aptose Biosciences' stock. Their predictions range from $6.00 to $7.00. On average, they anticipate Aptose Biosciences' share price to reach $6.3333 in the next twelve months. View Analyst Ratings for Aptose Biosciences.
Who are some of Aptose Biosciences' key competitors?
Some companies that are related to Aptose Biosciences include Surface Oncology (SURF), PDL Biopharma (PDLI), Idera Pharmaceuticals (IDRA), Nightstar Therapeutics (NITE), Adverum Biotechnologies (ADVM), Jounce Therapeutics (JNCE), Agenus (AGEN), NanoString Technologies (NSTG), Allena Pharmaceuticals (ALNA), NantKwest (NK), Cellular Biomedicine Group (CBMG), Osiris Therapeutics (OSIR), ADMA Biologics (ADMA), Arsanis (ASNS) and Organovo (ONVO).
Who are Aptose Biosciences' key executives?
Aptose Biosciences' management team includes the folowing people:
- Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
- Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
- Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
- Mr. Peter Murray, Director of Clinical Devel.
Has Aptose Biosciences been receiving favorable news coverage?
News articles about APTO stock have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptose Biosciences earned a coverage optimism score of 0.03 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.86 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Aptose Biosciences' major shareholders?
Which institutional investors are buying Aptose Biosciences stock?
How do I buy shares of Aptose Biosciences?
Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptose Biosciences' stock price today?
One share of APTO stock can currently be purchased for approximately $3.60.
How big of a company is Aptose Biosciences?
Aptose Biosciences has a market capitalization of $118.44 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 23 workers across the globe.
How can I contact Aptose Biosciences?
Aptose Biosciences' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]
MarketBeat Community Rating for Aptose Biosciences (APTO)
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aptose Biosciences (NASDAQ:APTO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Aptose Biosciences in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 75.93%. The high price target for APTO is $7.00 and the low price target for APTO is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.3333 | $6.3333 | $6.00 | $5.3333 |
| Price Target Upside: | 75.93% upside | 75.93% upside | 233.33% upside | 180.70% upside |
Aptose Biosciences (NASDAQ:APTO) Consensus Price Target History
Aptose Biosciences (NASDAQ:APTO) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Aptose Biosciences (NASDAQ:APTO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aptose Biosciences (NASDAQ APTO) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 1.54%
Aptose Biosciences (NASDAQ APTO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Aptose Biosciences (NASDAQ APTO) News Headlines
| Source: |
|
Aptose Biosciences (NASDAQ:APTO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aptose Biosciences (NASDAQ:APTO) Income Statement, Balance Sheet and Cash Flow Statement
Aptose Biosciences (NASDAQ APTO) Stock Chart for Sunday, May, 27, 2018
Loading chart…
